Caroline Stokke

List of Publications by Year
in descending order

32 papers	709 citations	623734 14 h-index	552781 26 g-index
33 all docs	33 docs citations	33 times ranked	794 citing authors

#	Article	IF	Citations
1	Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force. EJNMMI Physics, 2017, 4, 27.	2.7	71
2	EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1778-1809.	6.4	70
3	Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. EJNMMI Physics, 2017, 4, 28.	2.7	65
4	EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres. EJNMMI Physics, 2021, 8, 77.	2.7	61
5	How to measure CT image quality: Variations in CT-numbers, uniformity and low contrast resolution for a CT quality assurance phantom. Physica Medica, 2014, 30, 521-526.	0.7	51
6	An Easy-To-Use Simulation Program Demonstrates Variations in Bacterial Cell Cycle Parameters Depending on Medium and Temperature. PLoS ONE, 2012, 7, e30981.	2.5	50
7	Replication patterns and organization of replication forks in Vibrio cholerae. Microbiology (United) Tj ETQq1 1 0.784314 rgBT /Overlo	1.8	46
8	EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours. EJNMMI Physics, 2020, 7, 15.	2.7	44
9	Amyloid-Î² PETâ€"Correlation with cerebrospinal fluid biomarkers and prediction of AlzheimerÂ´s disease diagnosis in a memory clinic. PLoS ONE, 2019, 14, e0221365.	2.5	37
10	Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Advances, 2020, 4, 4091-4101.	5.2	33
11	Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate ^{177}Lu-Lilotomab Satetraxetan. Journal of Nuclear Medicine, 2017, 58, 48-54.	5.0	29
12	Red Marrowâ€"Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with ^{177}Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibodyâ€"Radionuclide Conjugate. Journal of Nuclear Medicine, 2017, 58, 55-61.	5.0	22
13	Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1233-1241.	6.4	21
14	Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibodyâ€"Radionuclide Conjugate^{177}Lu-Lilotomab Satetraxetan. Journal of Nuclear Medicine, 2018, 59, 704-710.	5.0	16
15	Short-course PET based simultaneous integrated boost for locally advanced cervical cancer. Radiation Oncology, 2016, 11, 39.	2.7	14
16	Comparison of [18F]fluciclovine and [18F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients. Molecular Imaging and Biology, 2022, 24, 842-851.	2.6	12
17	Regional myocardial work by cardiac magnetic resonance and non-invasive left ventricular pressure: a feasibility study in left bundle branch block. European Heart Journal Cardiovascular Imaging, 2020, 21, 143-153.	1.2	10
18	Escherichia coli SeqA Structures Relocalize Abruptly upon Termination of Origin Sequestration during Multifork DNA Replication. PLoS ONE, 2014, 9, e110575.	2.5	9

#	ARTICLE	IF	CITATIONS
19	New distinct compartments in the G_2 phase of the cell cycle defined by the levels of Ι³H2AX.. Cell Cycle, 2015, 14, 3261-3269.	2.6	7
20	FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1902-1914.	6.4	6
21	Evaluation of semi-quantitative measures of 18F-flutemetamol PET for the clinical diagnosis of Alzheimer's disease. Quantitative Imaging in Medicine and Surgery, 2022, 12, 493-509.	2.0	6
22	The Effect of New Formulas for Lean Body Mass on Lean-Body-Mass–Normalized SUV in Oncologic ^{18}F-FDG PET/CT. Journal of Nuclear Medicine Technology, 2018, 46, 253-259.	0.8	5
23	Myelosuppression in patients treated with ^{177}Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable. Acta Oncológica, 2021, 60, 1481-1488.	1.8	5
24	Combining radioiodine and external beam radiation therapy: the potential of integrated treatment planning for differentiated thyroid cancer. Acta Oncológica, 2017, 56, 894-897.	1.8	3
25	A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma. Blood, 2014, 124, 3094-3094.	1.4	3
26	New Targets for PET Imaging of Myeloma. Hemato, 2021, 2, 727-738.	0.6	3
27	FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target?. Molecular Imaging and Biology, 2022, 24, 807-817.	2.6	3
28	Respiratory motion during ^{90}Yttrium PET contributes to underestimation of tumor dose and overestimation of normal liver tissue dose. Acta Radiologica, 2018, 59, 132-139.	1.1	2
29	177lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens. Blood, 2016, 128, 1780-1780.	1.4	2
30	Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?. Journal of Alzheimer's Disease, 2021, , 1-9.	2.6	2
31	Left ventricular regional glucose metabolism in combination with septal scar extent identifies CRT responders. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2437-2446.	6.4	1
32	Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin®) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL). Blood, 2015, 126, 5118-5118.	1.4	0